acamprosate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
38 77337-76-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • acamprosaic acid
  • acamprosate
  • campral
  • zulex
  • acamprosate calcium
  • calcium acetylhomotaurinate
  • N-acetylhomotaurine
  • calcium acetylhomotaurine
The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. In vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.
  • Molecular weight: 181.21
  • Formula: C5H11NO4S
  • CLOGP: -2.47
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 83.47
  • ALOGS: -0.98
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 71.27 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 11 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.75 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 29, 2004 FDA FOREST LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal alcohol syndrome 70.73 49.77 7 135 6 2357937

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoventilation 73.89 39.84 12 171 535 1746063
Cardiovascular disorder 61.10 39.84 13 170 2544 1744054
Overdose 40.84 39.84 14 169 16687 1729911

Pharmacologic Action:

SourceCodeDescription
ATC N07BB03 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in alcohol dependence
MeSH PA D000427 Alcohol Deterrents
CHEBI has role CHEBI:35942 neurotransmitter agent
MeSH PA D002491 Central Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Alcoholism indication 7200002
Suicidal thoughts contraindication 6471006
Acute nephropathy contraindication 58574008
Impaired renal function disorder contraindication 197663003

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.21 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate [NMDA] receptor Ion channel ANTAGONIST CHEMBL CHEMBL
GABA-A receptor alpha-1/beta-3/gamma-2 Ion channel POSITIVE MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
D000077443 MESH_DESCRIPTOR_UI
4021476 VUID
N0000148859 NUI
C0284941 UMLSCUI
D02780 KEGG_DRUG
59375N1D0U UNII
77337-73-6 SECONDARY_CAS_RN
420804003 SNOMEDCT_US
4021476 VANDF
50782 MMSL
d04986 MMSL
391698009 SNOMEDCT_US
82819 RXNORM
005217 NDDF
71158 PUBCHEM_CID
CHEBI:51041 CHEBI
DB00659 DRUGBANK_ID
6473 INN_ID
7106 IUPHAR_LIGAND_ID
CHEMBL1201293 ChEMBL_ID
CHEMBL2068724 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0093-5352 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0378-6333 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 10135-636 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 42291-104 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 51079-241 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 60687-121 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 17 sections
Campral HUMAN PRESCRIPTION DRUG LABEL 1 68151-4760 TABLET, DELAYED RELEASE 333 mg ORAL NDA 16 sections
acamprosate calcium HUMAN PRESCRIPTION DRUG LABEL 1 68382-569 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections
Acamprosate Calcium HUMAN PRESCRIPTION DRUG LABEL 1 68462-435 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 17 sections
acamprosate calcium HUMAN PRESCRIPTION DRUG LABEL 1 70771-1057 TABLET, DELAYED RELEASE 333 mg ORAL ANDA 16 sections